Expanding our reach: ELF launches new partnering initiative for charities and foundations

With this move, the ELF aims to reach the larger drug discovery community and explore uncharted biological territory to address unmet medical needs.

The charities and foundations that enter into a collaboration with the ELF will gain access to a sub-set of our high-quality library of chemical compounds, industry-standard Ultra-High-Throughput and High Content Screening facilities, as well as access to the ELF network of drug discovery experts.

Through this initiative, the ELF hopes to boost charity-funded science, provide novel chemical starting points for the development of new treatments, and ultimately contribute to improving global health and well-being.

Follow in the steps of the Medicines for Malaria Venture and let’s work together to create an impact in the drug discovery space.

To find out more, follow this link, or contact the ELF programme office.
 

Useful links:

• In a paper published in Drug Discovery Today, partners of the ELF detail the properties of the ELF compound collection, showing that it is an attractive and “highly diverse” compound set that is complementary to commercial screening libraries
   
• Read this interview with the ELF Programme Clearance Team, a core team of individuals from Pivot Park Screening Centre and BioAscent responsible for selecting the best and most interesting compounds for ELF Programme Owners
   
• Find out about an ELF partnership that has led to ground-breaking new antibiotic research findings
   
• In a recent Comment in Nature Reviews Drug Discovery, members of the ELF illustrate the unique ELF concept, share progress, and provide an insight into future directions
   
• Read about how two drug candidates for cancer treatment that were identified with the help of the ELF have now progressed to clinical testing